Team

Verthermia is privileged to have the leading expert in whole body hyperthermia on the founding team. With over 30 years experience and known as the ‘grandfather’ of hyperthermia, Roger Vertrees, PhD, brings scientific stature. Another member of the team patented, developed and controls the highest market penetration for regional hyperthermia in North America showing the way to fast market adoption for Verthermia.

The team further includes

  • Pioneers in viral and chemistry filtration,
  • Highly experienced business, marketing and financial management,
  • MDs experienced in applying the procedure with living patients,
  • A full flushed set of recognized law, audit, and technology firms.

Finally, the addition of a recognized authority in advanced cancer treatments and head of surgical operations at Cleveland Clinic as Chief Medical Officer gives further legitimacy to the product offering.

Management

steve_scott_-_CIMG5332_-_300x375_-_verthermia_cancer-treatment

Steve Scott, MBA/JD

Chief Executive Officer

Growth & Turnaround Expert with 30 years of hands-on experience in leading companies to better their bottom line through building vision, dominating markets, rapid product development, organizational structuring and technology mix. Launched over 225 products successfully resulting in multiplying revenues up to ten times. Participated in over $400 million venture and public funding.

jim_felter_-_CIMG5318_-_300x375_-_verthermia_cancer-treatment

Jim Felter, MBA/CPA

Chief Financial Officer

36 years in financial management with a broad base of compliance accounting and forward thinking strategic planning with international, Fortune 500, large not-for-profits, hospital and long-term care, and privately held enterprises. Certified Public Accountant 29 years, MBA 10 years, Certified Information Technology Professional 10 years.

roger_vertrees_-_CIMG5313_-_300x375_-_verthermia_cancer-treatment

Roger Vertrees, Ph.D.

Chief Scientific Officer

Dr. Vertrees has 30 years’ of experience in hyperthermia basic science research as well as pre-clinical animal studies and was instrumental in the design of the only human trial to safely treat lung cancer patients in the US.

sri_chalikonda_-_300x375_-_verthermia_cancer-treatment

Sri Chalikonda, MD

Chief Medical Officer

Surgical oncologist at Cleveland Clinic. Chairman, Surgical Operations, Cleveland Clinic. Dr. Chalikonda has been treating patients with advanced abdominal cancer with regional hyperthermia since 3755. Pioneer in robotic surgery.

jan_winetz_-_CIMG5307_-_300x375_-_verthermia_cancer-treatment

Jan Winetz, M.D.

Chief Clinical Officer

Nephrologist is responsible for developing a proprietary algorithm to improve the overall margin of safety for WBH. Currently PI for the ovarian cancer trial. PI or management in over 50 clinical trials.

jeff_hall_-_CIMG5310_-_300x375_-_verthermia_cancer-treatment

Jeff Hall

VP Business Development

23 years medical sales. Johnson & Johnson and Schering Plough where he specialized in field training and implementation. He then transitioned to the medical device industry and has worked with Stryker, Applied Medical, Lanx, and Baxter Bio Surgery. His startup experience includes Intuitive Surgical and Power Medical both of which are considered pioneers in improving the way surgery is performed today.

rick_tullis_-_CIMG5325_-_300x375_-_verthermia_cancer-treatment

Rick Tullis, PhD

VP Manufacturing and Regulatory

Founder or co-founder of several biotechnology companies including Molecular Biosystems, Synthetic Genetics, DNA Sciences and Syngen Research. CEO, CSO or Board Member of one public and two private companies, Led or participated in two successful IPOs. Established and implemented GMP and GLP in several companies. 33 years experience in the research and development of extracorporeal therapeutic devices, DNA antisense therapeutics and diagnostics. Designed and directed four successful clinical trials for extracorporeal therapeutic device.

Board

  • Roger Vertrees, Chairman
  • Jan Winetz
  • Gary Keeling
  • Rick Tullis
  • Steve Scott

Advisors

gary_keeling_-_CIMG5296_-_300x375_-_verthermia_cancer-treatment

Gary Keeling

Commercial Adviser, Founder and Board Member

Pioneer in hyperthermia since 1993. First FDA clearance for regional hyperthermia. Received the first FDA IDE in the United States to administer Whole Body Hyperthermia, (WBH) in human clinical trials.
Created an entire new medical procedure commercially now known as HIPEC. The procedure is now used in over 150 premiere hospitals throughout the United States as standard of care for patients with advanced abdominal cancer. Established HIPEC programs at Memorial Sloan Kettering, MD Anderson, Massachusetts General, Cleveland Clinic, Mayo Clinic, University of California, Roswell Cancer Center, Mt. Sinai New York, University of Texas, University of Chicago, New York Presbyterian, University of Maryland, City of Hope and University of Wisconsin to name a few.

noel_messenger_-_300x375_-_verthermia_cancer-treatment

Noel Messenger, MBA

FDA Adviser

VP Regulatory and Clinical Affairs at BioVentrix, GDS (Guided Delivery Systems), Boston Scientific, Medtronic Vascular, and more.

jay_smith_-_CIMG5304_-_300x375_-_verthermia_cancer-treatment

Jay Smith, CPA / MBA

Business Advisor

33+ years experience in finance, accounting and operations. Expert knowledge in accounting, internal control systems, cost accounting, stock and reporting systems.

Collaborations

  • HemoCleanse, Steve Ash, MD, CEO and currently practicing nephrologist. Dr Ash has many patents to his credit, has shepherded several projects through the 510 K FDA process and is the developer of the carbon block sorbent technology.
  • Cardio Quip, Design and manufacture perfusion pumps and heat exchange systems.
  • Sandia Labs

Service Providers

  • Legal – Wilson Sonsini, Palo Alto, California
  • Audit – Haskell & White, Irvine, California